BXP vs. APH, AGY, ANCR, CEL, EAH, VLG, BMK, AVCT, 4BB, and HVO
Should you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Alliance Pharma (APH), Allergy Therapeutics (AGY), Animalcare Group (ANCR), Celadon Pharmaceuticals (CEL), ECO Animal Health Group (EAH), Venture Life Group (VLG), Benchmark (BMK), Avacta Group (AVCT), 4basebio (4BB), and hVIVO (HVO). These companies are all part of the "medical" sector.
Beximco Pharmaceuticals (LON:BXP) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 8.0%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 6.0%. Beximco Pharmaceuticals pays out 3,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Alliance Pharma pays out -20,000.0% of its earnings in the form of a dividend.
Beximco Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Alliance Pharma has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Alliance Pharma has a consensus price target of GBX 80.75, indicating a potential upside of 143.96%. Given Alliance Pharma's higher probable upside, analysts plainly believe Alliance Pharma is more favorable than Beximco Pharmaceuticals.
Beximco Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
1.6% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 71.0% of Alliance Pharma shares are held by institutional investors. 11.7% of Alliance Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alliance Pharma received 95 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. However, 64.67% of users gave Beximco Pharmaceuticals an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.
In the previous week, Beximco Pharmaceuticals and Beximco Pharmaceuticals both had 1 articles in the media. Beximco Pharmaceuticals' average media sentiment score of 0.88 beat Alliance Pharma's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.
Beximco Pharmaceuticals has a net margin of 11.80% compared to Alliance Pharma's net margin of -4.15%. Beximco Pharmaceuticals' return on equity of 10.29% beat Alliance Pharma's return on equity.
Summary
Beximco Pharmaceuticals beats Alliance Pharma on 11 of the 18 factors compared between the two stocks.
Get Beximco Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beximco Pharmaceuticals Competitors List
Related Companies and Tools
